EyePoint Pharmaceuticals (United Kingdom).
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
- Reports this week
- 2
- Active events
- 2
- Connections
- 29
What's happening
Active this week
-
Cantor Fitzgerald and Jefferies Financial Group downgraded EyePoint Pharmaceuticals' stock rating from overweight/buy to neutral/hold on October 19, 2026.Some support2 reports
-
EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Some support2 reports1 development inside
Earlier this month
One to three months ago
-
Ally Financial received a Strong Buy rating at $55 from Raymond James, while EyePoint Pharmaceuticals had its target slashed 80% to $4.Some support1 report
-
EyePoint Pharmaceuticals reported that Wet AMD is the leading cause of vision loss in the US.Some support2 reports1 development inside
-
EyePoint Pharmaceuticals developed Duravyu for wet AMD treatment.Some support1 report
-
MarketBeat is discussing EyePoint Pharmaceuticals, a company based in the United Kingdom, as a high-risk investment target.Some support1 report
-
Analyst firm issues research notes on EyePoint Pharmaceuticals, which is listed on the Nasdaq stock exchange.Some support3 reports
Gone quiet
No new reports in 90+ days-
Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.Some support3 reports
-
EyePoint Pharmaceuticals granted stock options under a NASDAQ listing rule on August 19, 2025.Some support3 reports1 development inside
-
Jay S. Duker leads EyePoint's execution across business aspects.Some support3 reports
-
Rhythm and EyePoint Pharmaceuticals are companies operating within the same industry.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around EyePoint Pharmaceuticals (United Kingdom) this week
News at the entities that move EyePoint Pharmaceuticals (United Kingdom) most-
Jay S. Duker StructuralJay S. Duker referenced findings from the Lugano clinical trial on October 19, 2026.Moves EyePoint Pharmaceuticals (United Kingdom)
-
FDA StructuralThe FDA approved a Skyrizi regimen for Crohn's disease, based on an AFFIRM trial led by UNC.Moves EyePoint Pharmaceuticals (United Kingdom)
-
Royal Bank of Canada OperationalRBC and Citigroup boosted price objectives on Lockheed Martin shares, with MarketBeat aggregating the analyst ratings.Moves EyePoint Pharmaceuticals (United Kingdom)
-
MarketBeat Mentioned togetherQT Imaging Holdings, Inc. was listed on the Nasdaq exchange and received consensus rating data from MarketBeat.Moves EyePoint Pharmaceuticals (United Kingdom)
-
Citigroup Mentioned togetherCitigroup reaffirmed its 'buy' rating for SPS Commerce, a company serving businesses across North America.Moves EyePoint Pharmaceuticals (United Kingdom)
-
Cantor Fitzgerald OperationalAvalo Therapeutics received multiple rating changes and analyst coverage from firms including Cantor Fitzgerald, Bank of America, and Weiss Ratings.Moves EyePoint Pharmaceuticals (United Kingdom)
Connections
The 12 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jay S. Duker Structural
Jay S. Duker holds the executive role of President and CEO at EyePoint Pharmaceuticals.
-
Nasdaq Structural
EyePoint Pharmaceuticals lists and trades its shares on the Nasdaq stock exchange.
-
FDA Structural
EyePoint Pharmaceuticals relies on the FDA for regulatory approval of its products.
-
Royal Bank of Canada Operational
RBC actively influences EyePoint's market perception through target price adjustments and sector ratings.
-
MarketBeat Mentioned together
MarketBeat reports and tracks consensus ratings and investment data for EyePoint Pharmaceuticals.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald provides financial ratings and price targets for EyePoint Pharmaceuticals, influencing its market perception.
-
Citigroup Mentioned together
Citigroup provides financial analysis, including buy ratings and price objectives, for EyePoint Pharmaceuticals.
-
company Mentioned together
EyePoint Pharmaceuticals is mentioned in the context of financial investigation within the broader corporate sector.
Show all 12 connections
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provided stock rating coverage for EyePoint Pharmaceuticals, including upgrades and downgrades.
-
GSK Operational
The two healthcare companies are actively compared, indicating market competition.
-
TD Cowen Mentioned together
TD Cowen provided financial analysis, slashing the target price for EyePoint Pharmaceuticals.
-
Y. Chen Mentioned together
Analyst research notes connect the two entities within market coverage.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsAugust 2026
3 eventsShow 1 earlier month
June 2026
7 events- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- Trump's pledge to unleash American oil and gas benefits certain stocks, impacting EyePoint Pharmaceuticals.
- EyePoint Pharmaceuticals reported that Wet AMD is the leading cause of vision loss in the US.
- Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.
- EyePoint Pharmaceuticals granted stock options under a NASDAQ listing rule on August 19, 2025.
- Jay S. Duker leads EyePoint's execution across business aspects.
- Rhythm and EyePoint Pharmaceuticals are companies operating within the same industry.